

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, September 29, 2017

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baak, MD		Bill Ladwig, RPh	X
Dana Darger, RPh		Kelley Oehlke, PharmD	X
James Engelbrecht, MD	X	Lenny Petrik, PharmD	X
Mikel Holland, MD	X	Timothy Soundy, MD	X
Richard Holm, MD, Chair	X	Mike Jockheck, DSS Staff	X

Administrative Business

The meeting was called to order by Holm at 1:00 PM. The minutes of the March meeting were presented. Soundy requested the minutes to reflect his attendance at the March meeting; March meeting minutes to be amended. Holm made a motion to approve. Oehlke seconded the motion. Motion was approved unanimously.

Introductions

The P&T meeting support transitioned from HID Designs to Optum. Committee members were introduced to the clinical pharmacist from OptumRx.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report for July 2017. There were a total of 2,595 PAs processed in the month of July, with 94.03% of those requests responded to in less than eight hours. There were 2001 requests (77%) received electronically and 594 requests (23%) received via fax.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from 4/1/2017 to 6/30/2017. The top five classes were antipsychotic agents, insulins, respiratory and CNS stimulants, amphetamines, and disease-modifying anti-rheumatic agents. The top 15 therapeutic classes make up 38.39% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 13.28% of total claims.

Opioid Strategies for Management Review

The committee reviewed the report of patients at each morphine equivalent dosage (MED) breakpoint. There were 114 patients taking over 300 MEDs. The committee asked for the geographical zip codes for these utilizations. The top prescribers were two physician assistants and a nurse practitioner. Engelbrecht requested more information regarding the supervising physician and appropriate use of utilization; in addition, the frequency of the physician assistants writing these prescription.

Soundy made a motion to send letters to the top 50 prescribers of opioids for the past year. Ladwig seconded the motion. The motion passed unanimously. Soundy also made a motion for an on-going opioid utilization report at every P&T meeting with the following information listed below. Holland seconded the motion. Motion passed unanimously. Ladwig requested the State to find out how other Medicaid states are managing opioids.

For patients with MED greater than 300:

1. Diagnosis
2. Age/gender
3. Concomitant therapy such as benzodiazepines, etc
4. Number of prescribers
5. Duration of opioid therapy

Review of Codeine and Tramadol Utilization

Committee reviewed the utilization of codeine and tramadol. For patients under 12 years old, there were claims for 10 patients for tramadol utilization; and 880 claims and 758 patients with codeine utilization. There were 384 unique prescribers of codeine for patients less than 12 years old. Soundy made a motion to send letters to these prescribers. Ladwig seconded the motion. Motion passed unanimously.

Dupixent Review

The committee reviewed Dupixent clinical information. Committee clarified the trial of a first-line agent as fluorinated steroid such as e.g. triamcinolone. There was no public comment. Engelbrecht made a motion to place Dupixent on prior authorization. Soundy seconded the motion. The motion was approved unanimously.

Xrylix Kit Review

The committee reviewed Xrylix Kit clinical information. Based on information that Xrylix Kit is not on the CMS covered outpatient drug file due to one component of the kit containing a medical supply item, committee decided not to place on prior authorization. There was no public comment. Engelbrecht made a motion to keep Xrylix Kit as a non-covered item. Ladwig seconded the motion. The motion was approved unanimously.

Zipsor/Zorvolex/Cambia Review

The committee reviewed Zipsor/Zorvolex/Cambia clinical information. There was no public comment. Ladwig made a motion to place Zipsor/Zorvolex/Cambia on prior authorization. Soundy seconded the motion. The motion was approved unanimously. Committee requested utilization information of these products at future meetings.

Optum Overview

OptumRx provided an overview of the administrative support services that will be provided to South Dakota Medicaid. These include PA services, system capabilities, reporting capabilities, and P&T committee support.

Jockcheck provided a brief update on candidates for a new P&T committee member. Committee discussed potential candidates.

Next meeting is scheduled for December 1, 2017. Ladwig made a motion to adjourn. Engelbrecht seconded. The meeting adjourned at 3:30 PM.